Amarin’s REDUCE-IT Analysis Shows RW-apoB Identifies 30% Higher Residual CV Risk
AMRN•Amarin’s post hoc analysis of 3,485 statin-treated patients over a median 4.9-year follow-up found risk-weighted ApoB levels averaged 30% higher than measured ApoB, identifying more residual cardiovascular risk than LDL-C, non-HDL-C or standard ApoB. Applying European Society of Cardiology thresholds flagged a larger high-risk cohort, supporting enhanced risk stratification.
1. Post Hoc REDUCE-IT Analysis
Amarin presented a post hoc evaluation of the REDUCE-IT placebo arm, examining risk-weighted apolipoprotein B (RW-apoB) in 3,485 statin-treated patients with elevated triglycerides over a median 4.9-year follow-up.
2. Superior Risk Prediction
The analysis found RW-apoB levels averaged 30% higher than measured ApoB and demonstrated improved cardiovascular event prediction compared with LDL-C, non-HDL-C, and standard ApoB metrics.
3. Implications for Clinical Practice
Applying European Society of Cardiology intervention thresholds using RW-apoB identified more high-risk patients than ApoB alone, suggesting potential for refined risk stratification and informing future guideline integration.
